Citation Impact
Citing Papers
Risk Factors for Venous Thromboembolism
2003 Standout
De novo design of allosterically switchable protein assemblies
2024 StandoutNatureNobel
Structural Insights into the Evolution of a Non-Biological Protein: Importance of Surface Residues in Protein Fold Optimization
2007 StandoutNobel
Biochemical and Enzymatic Characterization of Human Kallikrein 5 (hK5), a Novel Serine Protease Potentially Involved in Cancer Progression
2005
The Antithrombotic Activity and Pharmacokinetics of Enoxaparine, A Low Molecular Weight Heparin, In Humans Given Single Subcutaneous Doses of 20 to 80 mg
1988
Dominant forces in protein folding
1990 Standout
Sialic Acid Content of Plasminogen 2 Glycoforms as a Regulator of Fibrinolytic Activity
1995
Subcutaneous Low-Molecular-Weight Heparin Compared with Continuous Intravenous Heparin in the Treatment of Proximal-Vein Thrombosis
1992 Standout
The molecular basis of blood coagulation
1988 Standout
Systematic identification of allosteric protein-metabolite interactions that control enzyme activity in vivo
2013
Nitric Oxide and Peroxynitrite in Health and Disease
2007 Standout
Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold – A Potential Therapeutic Intervention for Skin Diseases
2016 StandoutNobel
The coagulation cascade: initiation, maintenance, and regulation
1991 Standout
Peroxynitrite and fibrinolytic system: The effect of peroxynitrite on plasmin activity
2004
Cerebral Sinovenous Thrombosis in Children
2001 Standout
Resistance to Activated Protein C as a Basis for Venous Thrombosis
1994 Standout
Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation
1991 Standout
The course and prerequisites of Lys-plasminogen formation during fibrinolysis
1988
World distribution of factor V Leiden
1995 Standout
Prothrombotic Disorders in Infants and Children With Cerebral Thromboembolism
1998
Isolation and characterization of plasminogen activators from hyperlastic and malignant prostate tissue
1984
Conformation of one- and two-chain high molecular weight urokinase analyzed by small-angle neutron scattering and vacuum ultraviolet circular dichroism
1991 StandoutNobel
Bovine chymotrypsinogen A
1985 StandoutNobel
Influence of cyanogen-bromide-digested fibrinogen on the kinetics of plasminogen activation by urokinase
1984
Recurrent Venous Thromboembolism in Patients with a Partial Deficiency of Protein S
1984
Deficiency of protein C in congenital thrombotic disease.
1981 Standout
Probes of the mechanism of zymogen catalysis
1978
Plasma protein S deficiency in familial thrombotic disease
1984
On the Regulation and Control of Fibrinolysis
1980
Spectroscopic studies of protein-heme interactions accompanying the allosteric transition in methemoglobins
1985 StandoutNobel
Extended x-ray absorption fine structure—its strengths and limitations as a structural tool
1981 Standout
Regulation of the endothelial cell urokinase-type plasminogen activator receptor. Evidence for cyclic AMP-dependent and protein kinase C-dependent pathways.
1993 StandoutNobel
Probing the energetics of proteins through structural perturbation: sites of regulatory energy in human hemoglobin.
1982
Plasminogen Activators, Tissue Degradation, and Cancer
1985 Standout
Functional characteristics of receptor-bound urokinase on human monocytes: catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors
1989
Fibrin as a component of the tumor stroma: origins and biological significance
1983
GLOBIN MESSENGER RNA IN THE THALASSEMIA SYNDROMES*
1974 StandoutNobel
NUCLEOTIDE SEQUENCES OF HUMAN GLOBIN MESSENGER RNA *
1974 StandoutNobel
Energy-structure correlation in metalloporphyrins and the control of oxygen binding by hemoglobin.
1977 StandoutNobel
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis
1996 Standout
A SENSITIVE, COUPLED ASSAY FOR PLASMINOGEN ACTIVATOR USING A THIOL ESTER SUBSTRATE FOR PLASMIN*
1981
Internally quenched fluorescent peptide substrates disclose the subsite preferences of human caspases 1, 3, 6, 7 and 8
2000 StandoutNobel
Amino Acid Difference Formula to Help Explain Protein Evolution
1974 StandoutScience
The rate of carbon monoxide binding to hemoglobin Kansas
1972 StandoutNobel
Nucleotide Sequences of Human Globin Messenger RNA
1974 StandoutNobel
Tissue-type plasminogen activator increases the binding of glu-plasminogen to clots.
1984
Haemoglobin Constant Spring—A Chain Termination Mutant ?
1971 Nature
Stimulation of tissue plasminogen activator by denatured proteins and fibrin clots: A possible additional role for plasminogen activator?
1981
3′ Non-coding region sequences in eukaryotic messenger RNA
1976 StandoutNature
Glycobiology: Toward Understanding the Function of Sugars
1996 Standout
Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C.
1993 Standout
Molecular Pathology of Human Haemoglobin
1968 Nature
Activation of plasminogen to plasmin by a protease associated with the outer membrane of Escherichia coli.
1981
Interaction of single-chain urokinase-type plasminogen activator with human endothelial cells.
1990 StandoutNobel
Evolution of serum albumin
1977 StandoutNobel
Origins of the specificity of tissue-type plasminogen activator.
1995
Spontaneous missense mutation of an immunoglobulin in a mouse myeloma cell line
1977 StandoutNobel
The plasminogen activator and esterase activities of the two forms of urokinase
1981
Characterization of an Extremely Large, Ligand-Induced Conformational Change in Plasminogen
1990 StandoutScienceNobel
Epidemiology of coagulation disorders
1992
The Atomic Structure of Erythrocruorin in the Light of the Chemical Sequence and its Comparison with Myoglobin
1971 StandoutNobel
Sunflower trypsin inhibitor (SFTI-1) analogues of synthetic and biological origin via N→S acyl transfer: potential inhibitors of human Kallikrein-5 (KLK5)
2014 StandoutNobel
Matrix Proteases in Health and Disease
2012
Structure-function relations in hemoglobin as determined by x-ray absorption spectroscopy.
1976
Role of the lysine binding regions in the kinetic properties of human plasmin
1981
An allosteric model of hemoglobin
1972 StandoutNobel
A fluorescent study of urokinase using active-site directed probes
1982
Genetic Heterogeneity
1968
The effects of fibrinogen and its cleavage products on the kinetics of plasminogen activation by urokinase and subsequent plasmin activity.
1983
Familial Hypercholesterolemia in a Large Kindred
1972 StandoutNobel
Proteolytic activation of latent transforming growth factor-beta from fibroblast-conditioned medium.
1988 Standout
Homology between human bladder carcinoma oncogene product and mitochondrial ATP-synthase
1983 StandoutNatureNobel
Molecular analysis of spontaneous somatic mutants
1977 StandoutNatureNobel
Small Molecule–Macromolecule Interactions as Studied by Optical Rotatory Dispersion–Circular Dichroism
1970
Repeating sequences and gene duplication in proteins
1972
Spectroscopic studies of Cibacron Blue and Congo Red bound to dehydrogenases and kinases. Evaluation of dyes as probes of the dinucleotide fold
1979 StandoutNobel
Venous thrombosis: a multicausal disease
1999 Standout
Tumors: Wounds That Do Not Heal
1986 Standout
Isolation of plasminogen activator from human plasma by chromatography on lysine-Sepharose
1978
Thromboembolic Disease – Critical Evaluation of Laboratory Investigation
1992
Positive regulation of activation of plasminogen by urokinase: differences in Km for Glu- and Lys-plasminogen and the effect of .alpha.,.omega.-amino acids
1982
A functionally active heavy chain derived from human high molecular weight urokinase.
1983
L-Threonine Dehydrase as a Model of Allosteric Control Involving Ligand-lnduced Oligomerization
1975
Internally quenched fluorescent peptide substrates disclose the subsite preferences of human caspases 1, 3, 6, 7 and 8
2000 StandoutNobel
Hemoglobin casper: β 106 (G8) Leu→Pro
1973
Agonist-induced increase in apparent β-adrenergic receptor size
1978 StandoutNobel
Purification of an inhibitor of plasminogen activator (antiactivator) synthesized by endothelial cells.
1984 Standout
A quantitative assay for the activation of plasminogen by transformed cells in situ and by urokinase
1981
The role of fragment X polymers in the fibrin enhancement of tissue plasminogen activator-catalyzed plasmin formation.
1990 StandoutNobel
Works of Robert C. Wohl being referenced
A virgin enzyme derived from human plasminogen. Specific cleavage of the Arg560-Val peptide bond in the DIP-virgin enzyme by plasminogen activators
1982
Comparison of the esterase and human plasminogen activator activities of various activated forms of human plasminogen and their equimolar streptokinase complexes.
1977
Kinetics of activation of human plasminogen by different activator species at pH 7.4 and 37 degrees C.
1980
PLASMJN AND PLASMINOGEN ACTIVATORS: KINETICS, AND KINETICS OF PLASMINOGEN ACTIVATION
1981
Functional Properties of Hemoglobin Kempsey
1974
Physiological activation of the human fibrinolytic system. Isolation and characterization of human plasminogen variants, Chicago I and Chicago II.
1979
Hemoglobin Gun Hill: Deletion of Five Amino Acid Residues and Impaired Heme-Globin Binding
1967 Science
Methods for studying fibrinolytic pathway components in human plasma
1982
Phosphoenolpyruvate Carboxylase of Escherichia coli
1972
Structure and formation of microplasmin.
1987
Comparative activation kinetics of mammalian plasminogens
1983
Investigation of a Congenital Abnormal Plasminogen, Frankfurt I, and Its Relationship to Thrombosis
1986
Stroke in a young adult with familial plasminogen disorder.
1991
Steady state kinetics of activation of human and bovine plasminogens by streptokinase and its equimolar complexes with various activated forms of human plasminogen.
1978